病理催化物理涂层恢复了炎症性肠道疾病治疗的肠道屏障
Yuge Zhao1, Ruiqing He1, Jie Zang1
1Shanghai Tenth People's Hospital, The Institute for Biomedical Engineering & Nano Science (iNANO), School of Medicine, Tongji University, Shanghai, 200092, China.
Journal of nanobiotechnology
|November 23, 2023
概括
这项研究引入了一种新的催化酶催化涂层策略,用于修复炎症性肠病 (IBD) 中受损的肠壁. 聚多巴胺涂层有效地封闭泄漏并减少炎症,提供了一种新的物理治疗方法.
科学领域:
- 生物医学工程 生物医学工程
- 胃肠病学 胃肠病学
- 材料科学 材料科学 材料科学
背景情况:
- 炎症性肠病 (IBD) 涉及肠上皮质屏障功能障碍,导致免疫失衡.
- 目前用于恢复IBD上皮屏障的治疗策略有限,缺乏临床疗效.
- 在IBD的病理环境中含有催化酶 (CAT),具有治疗点.
研究的目的:
- 开发一种催化酶催化涂层,用于修复IBD中受损的肠上皮屏障.
- 研究聚多巴胺 (PDA) 涂层在抑制肠道泄漏和减少炎症方面的潜力.
- 建立物理修复策略,作为IBD治疗中药物管理的替代方案.
主要方法:
- 一个纳米系统共同提供过氧化 (CaO2) 和多巴胺被设计为in-situ涂层.
- 在病理环境中,催化酶 (CAT) 催化了CaO2产生氧 (O2),从而启动了多巴胺聚合.
- 粘合剂聚多巴胺 (PDA) 在受损的肠道屏障上形成了一个整合性涂层.
主要成果:
- 在体内研究表明,PDA涂层有效地限制了肠道泄漏.
- 在IBD模型中,PDA涂层表现出有利的抗炎作用.
- 催化涂层策略被证明是一种可行的物理修复方法.
结论:
- 催化酶催化聚多巴胺涂层代表了炎症性肠病的有前途的物理治疗方法.
- 这种方法为恢复肠道屏障完整性和管理IBD中的免疫失衡提供了一种新的策略.
- 这些发现表明IBD治疗的新方向超出了传统的基于药物的干预措施.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
132
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
132
Inflammatory Bowel Disease V: Surgical Management
148
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
148
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
337
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
337
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
146
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
146


